Swedish nationwide study of 377 patents with non-aneurysmal subarachnoid haemorrhage: a disease with distinct demographics and risk factors

瑞典一项针对377例非动脉瘤性蛛网膜下腔出血患者的全国性研究:一种具有独特人口统计学特征和风险因素的疾病

阅读:3

Abstract

BACKGROUND: Non-aneurysmal subarachnoid haemorrhage (NASAH) accounts for less than 20% of spontaneous subarachnoid haemorrhage (SAH). However, its epidemiological characteristics, risk factors and aetiology remain poorly defined. METHODS: All patients with spontaneous SAH admitted to a neurosurgical centre in Sweden over a 3.5-year period were prospectively enrolled in a database. Epidemiological data, risk factors, Fisher grade and follow-up radiological findings were analysed, comparing NASAH cases to aneurysmal SAH (aSAH). RESULTS: A total of 1532 patients with SAH were included, of whom 377 (24.6%) were diagnosed with NASAH. Five NASAH patients exhibited microaneurysms in the perforating arteries (MAPAs) of the vertebrobasilar circulation, identified on follow-up cone-beam CT angiography. Gender distribution and Fisher grade presentation differed significantly between the NASAH and aSAH groups (p<0.001). Risk factors, such as smoking, hypertension and alcohol overuse, were significantly more common in aSAH than NASAH. Conversely, diabetes mellitus (DM) was more prevalent in NASAH than in aSAH (p<0.001). CONCLUSIONS: This is the largest epidemiological study of NASAH to date. The observed incidence of NASAH was higher than in the previous reports, suggesting either underdiagnosis in earlier studies or a changing proportion of aSAH to NASAH cases. The distinct differences in population characteristics and risk factors suggest that NASAH and aSAH arise from fundamentally different pathophysiological mechanisms. DM emerged as a risk factor for NASAH, and MAPAs were identified as one of the underlying sources of haemorrhage in this subgroup.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。